| Item 1. | Security and Issuer |
| (a) | Title of Class of Securities:
Common Stock, par value $0.001 per share |
| (b) | Name of Issuer:
Q/C TECHNOLOGIES, INC. |
| (c) | Address of Issuer's Principal Executive Offices:
1185 AVENUE OF THE AMERICAS, SUITE 249, NEW YORK,
NEW YORK
, 10036. |
Item 1 Comment:
This Schedule 13D relates to the shares of common stock, par value $0.001 ("Common Stock"), of Q/C Technologies, Inc. (the "Issuer"). The principal executive offices of the Issuer are located at 333 Bush Street, Suite 1400, San Francisco, CA 94104. The Common Stock is listed on The Nasdaq Capital Market under the symbol "QCLS". |
| Item 3. | Source and Amount of Funds or Other Consideration |
| | Item 3 is hereby amended and supplemented as follows:
"On July 31, 2026, in connection with the Issuer's declaration of Series G Dividends for the months of February through July, the Reporting Person acquired an additional 127,296 shares of Common Stock at a valuation of $3.3717 per share. On October 1, 2026, in connection with the Issuer's declaration of Series G Dividends for the months of July through September, the Reporting Person acquired an additional 42,432 shares of Common Stock at a valuation of $3.3717 per share. No additional cash was paid by the Reporting Person in connection with the acquisition of these additional shares of Common Stock.
On November 18, 2026, in connection with the Consent Agreement described in Item 4 below, the Reporting Person acquired 4,982,272 shares of Common Stock in exchange 851,304 Series G Long-Term Warrants.
No additional cash was paid by the Reporting Person in connection any of these acquisitions of additional shares of Common Stock. " |
| Item 4. | Purpose of Transaction |
| | Item 4 is hereby amended and supplemented as follows:
"Consent and Warrant Exchange Agreement. On November 15, 2026, the Reporting Person entered into a Consent and Warrant Exchange Agreement with the Issuer (the "Consent Agreement"), pursuant to which the Reporting Person agreed to exchange 851,304 Series G Long-Term Warrants (the "Exchange Warrants") for an aggregate of 4,982,272 shares of Common Stock (the "Exchange Shares"). The number of Exchange Shares equals the Black-Scholes value of the Exchange Warrants divided by $0.3101 per share, the closing price of the Common Stock on the last trading day before the Consent Agreement was signed. The Exchange Shares were delivered to the Reporting Person on November 18, 2026. In addition, pursuant to the Consent Agreement, the Reporting Person consented to an amendment to the Certificate of Designations extending the maturity date of the Series H Preferred Shares from March 2, 2027 to September 2, 2027 (the "Series H Maturity Amendment"), for no additional consideration. The foregoing descriptions of the Consent Agreement and the Series H Maturity Amendment are qualified in their entirety by reference to the full text of such documents, which are filed as, or incorporated by reference to the filings identified in, Exhibits 10 and 11 to this Schedule 13D and are incorporated herein by reference.
On November 20, 2026, the Reporting Person and the Issuer entered into an Omnibus Amendment Agreement (the "Omnibus Agreement"). The Reporting Person holds at least a majority of the outstanding shares of each of the Series G Preferred Stock and the Series H Preferred Stock and thereby constitutes the Required Holders (as defined in the applicable Certificate of Designations). Pursuant to the Omnibus Agreement, the Reporting Person and the Issuer agreed to amend (i) the Series G Certificate of Designations by filing a Certificate of Amendment (the "Series G Amendment") with the Secretary of State of the State of Delaware, (ii) the Series H Certificate of Designations by filing a Certificate of Amendment (the "Series H Beneficial Amendment") with the Secretary of State of the State of Delaware, and (iii) the Series G Long-Term Warrants held by the Reporting Person to amend the amendment provisions and the beneficial ownership limitation provisions contained therein. Under the amended beneficial ownership limitation provisions (the "Beneficial Ownership Limitation"), the Reporting Person may not convert any Series G Preferred Stock or Series H Preferred Stock, or exercise any Series G Long-Term Warrants, to the extent that after giving effect to the conversion or exercise it, together with its affiliates and any other persons whose beneficial ownership would be aggregated with it for purposes of Section 13(d) of the Exchange Act, would beneficially own more than 49.99% of the outstanding Common Stock.
The foregoing descriptions of the Omnibus Agreement, the Series H Beneficial Amendment and the Series G Amendment are qualified in their entirety by reference to the full text of such documents, which are filed as, or incorporated by reference to the filings identified in, Exhibits 12, 13 and 14 to this Schedule 13D and are incorporated herein by reference." |
| Item 5. | Interest in Securities of the Issuer |
| (a) | See Items 7-13 of the cover pages and Item 2 of this Schedule 13D. |
| (b) | See Items 7-13 of the cover pages and Item 2 of this Schedule 13D. |
| (c) | Except as described in Item 3 and Item 4 of this Schedule 13D, which descriptions are incorporated herein by reference, the Reporting Person has not effected any transactions in the Common Stock during the past 60 days. |
| (d) | No other person is known to the Reporting Person to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, any securities covered by this Schedule 13D. |
| (e) | Not applicable. |
| Item 6. | Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer |
| | Item 6 is hereby amended and supplemented as follows:
"The information set forth in Item 4 is incorporated by reference in its entirety into this Item 6." |
| Item 7. | Material to be Filed as Exhibits. |
| | Item 7 is hereby amended and supplemented as follows:
"10. Consent and Warrant Exchange Agreement, dated as of November 15, 2026, by and between Q/C Technologies, Inc. and PharmaCyte Biotech, Inc. (incorporated by reference to Exhibit 10.5 to the Issuer's Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed with the SEC on November 16, 2026)
11. Certificate of Amendment to the Certificate of Designations of Series H Convertible Preferred Stock (maturity date amendment) (incorporated by reference to Exhibit 3.3 to the Issuer's Current Report on Form 8-K filed with the SEC on November 20, 2026).
12. Certificate of Amendment to the Certificate of Designations of Series G Convertible Preferred Stock (beneficial ownership limitation) (incorporated by reference to Exhibit 3.1 to the Issuer's Current Report on Form 8-K filed with the SEC on November 20, 2026).
13. Certificate of Amendment to the Certificate of Designations of Series H Convertible Preferred Stock (beneficial ownership limitation) (incorporated by reference to Exhibit 3.2 to the Issuer's Current Report on Form 8-K filed with the SEC on November 20, 2026).
14. Omnibus Amendment Agreement, dated as of November 20, 2026, by and between Q/C Technologies, Inc. and PharmaCyte Biotech, Inc. (incorporated by reference to Exhibit 10.1 to the Issuer's Current Report on Form 8-K filed with the SEC on November 20, 2026)." |